Ian F. Smith
CEO & DirectorMr. Ian F. Smith, CPA, ACA, is CEO of Stoke Therapeutics, Inc. from October 6, 2025 and serves as its Director since September 19, 2023 and served as its Interim CEO from March 19, 2025 to October 6, 2025. He is Director of Areteia Therapeutics, Inc. from March 26, 2025. He is an Independent Director at Odyssey Therapeutics Inc. from August 2024. He serves as Member of Strategic Advisory Board of iVexSol Inc. since May 2023 and serves as its Board of Directors Member since August 2023. He serves as Chairman of the Board of Rivus Pharmaceuticals, Inc. since November 2023. He serves as Independent Director at Foghorn Therapeutics Inc. since April 27, 2021. Mr. Smith serves as Chairperson of the Board of ViaCyte, Inc since 2021 and had been Executive Chairperson from July 2019 to September 2022 and serves as its Director since July 24, 2019. He serves as Director at Solid Biosciences Inc. since April 15, 2020 serves as its Executive Chair since January 2022 and served as its Chairman of the Board since June 16, 2020 until January 2022. Mr. Smith serves as a Senior Advisor to Bain Capital Life Sciences, which position he has held since January 2021. Mr. Smith served as a Director of Acorda Therapeutics, Inc. from February 2007 to January 25, 2019. He was an Executive Vice President of Vertex Pharmaceuticals Inc. from February 2006 to January 23, 2019 and served as its Chief Operating Officer from January 1, 2017 to January 23, 2019. Mr. Smith was an Interim Chief Financial Officer of Vertex Pharmaceuticals Incorporated from December 13, 2018 to January 23, 2019. He serves as a Director of AavantiBio. He served as Senior Vice President of Vertex Pharmaceuticals Incorporated from November 2003 to February 2006 and Vice President from October 2001 to November 2003. Mr. Smith served as a Member of the Executive Team of Vertex Pharmaceuticals Incorporated and holds responsibility for a wide variety of core functions, including Finance, Strategic Communications, Information Systems, Operations and Human Resources. He served as the Chief Financial Officer at Vertex Pharmaceuticals Incorporated since October 2001 until September 13, 2017. He joined Vertex in October 2001. He has extensive expertise in financial operations and financing strategies for high growth life science companies. From 1999 to 2001, Mr. Smith served as a Partner in the Life Science and Technology Practice Group of Ernst & Young LLP. Mr. Smith joined Vertex from Ernst & Young LLP where he served as a Partner in their Life Science and Technology Practice from 1999 to 2001. Mr. Smith joined Ernst & Young's U.K. firm in 1987 and then joined their Boston office in 1995. He holds responsibility for core functions at Vertex, including Finance and Accounting, Investor Relations, Corporate and Business Development, Global Information Systems and Worldwide Operations and he is a Member of the Executive Team. Mr. Smith has been a Director of Tolerx, Inc. since April 5, 2004 and EPIX Pharmaceuticals, Inc. since August 16, 2006. He served as a Director of Infinity Pharmaceuticals, Inc. since May 2008 until January 27, 2019. He serves as a Member of the American Institute of Certified Public Accountants and the Institute of Chartered Accountants of England and Wales and the Financial Executives Institute. Mr. Smith has extensive global financial and accounting experience and possesses an understanding of financial matters and the preparation and analysis of financial statements. He served as a Director of Predix Pharmaceuticals Holdings Inc. since May 2005 and Predix Pharmaceuticals, Inc. since June 2, 2005. He serves as Director of Alkeus Pharmaceuticals, Inc. since December 2022. He served as a Director at Ophthotech Corporation from August 2, 2016 to May 19, 2017. Mr. Smith had been Executive Chair of the board of ViaCyte, Inc., a private biotechnology company from July 2019 to September 2022. Mr. Smith graduated with honors from Manchester Metropolitan University, United Kingdom, where he holds a B. A. Degree majored in Accounting and Finance.
Positions
- Company NameStoke Therapeutics, Inc.Stock CodeSTOKPositionCEO & DirectorColleagues
- IFIan F. SmithCEO & Director
- AOArthur O. TzianabosChairman of the Board
- ARAdrian R. KrainerCo-Founder & Independent Director
- TEThomas Edward LeggettChief Financial Officer
- JHJason HoittChief Patient Officer
- IAIsabel AznarezCo-Founder & CTO
- AAArthur A. LevinIndependent Director
- JCJennifer C. BursteinIndependent Director
- Company NameSolid Biosciences Inc.Stock CodeSLDBPositionExecutive ChairColleagues
- Company NameOdyssey Therapeutics, Inc.Stock CodeODTXPositionIndependent DirectorColleagues
- GDGary D. GlickFounder, President, CEO & Director
- JMJeffrey Marc LeidenIndependent Chairman of the Board
- JHJason HaasChief Financial Officer
- CTCollin ToddSenior Vice President of Strategy & Business Development
- ELEicke LatzScientific Co-Founder
- KLKim LewisScientific Co-Founder
- SCStephen C. BlacklowChairman of Scientific Advisory Board
- VOValerie OdegardIndependent Director
